"The
Report PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US
Drug Forecast and Market Analysis to 2022 provides information on
pricing, market analysis, shares, forecast, and company profiles for
key industry participants. - MarketResearchReports.biz"
The first prophylactic vaccine
for immunization against human papillomavirus (HPV) became available
in 2006. The global HPV vaccines market is now well established, yet
vaccine coverage rates amongst the traditional target population of
adolescent girls remain persistently low. Initially HPV vaccines were
developed and marketed solely to protect against cervical cancer. In
recent years the role of HPV in other cancers has been increasingly
recognized which has facilitated a shift towards vaccinating a wider
population, most significant has been the inclusion of males in
routine vaccine recommendations in some countries. The current HPV
vaccines market is dominated by one major player, Mercks Gardasil,
with GlaxoSmithKlines (GSKs) HPV vaccine Cervarix providing the only
competition. The introduction of Mercks nine-valent vaccine (V503) is
set to change the future landscape of the HPV vaccines sector.
In the US the total number of
HPV vaccine doses delivered annually is likely to grow steadily over
the next few years, as more males receive vaccination and Mercks
nine-valent vaccine V503 becomes available in 2015. US market growth
will contribute to global growth in the HPV vaccines sector. There is
no indication that coverage rates for adolescent girls will increase
dramatically over the forecast period, as they have been relatively
stable over the past few years. However, a modest increase will
likely be achieved following the introduction of V503, which will be
accompanied by a marketing and awareness campaign.
View Report At
:http://www.marketresearchreports.biz/analysis/210570
Scope
- Overview of Prophylactic
Human Papillomavirus Vaccines including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
- Detailed information on the
key drugs in the US including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in the US from 2012-2022.
- Analysis of the impact of key
events as well the drivers and restraints affecting the US
Prophylactic Human Papillomavirus Vaccines disease market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for Prophylactic
Human Papillomavirus Vaccines
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2012-2022 in the US
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/210570
Table
of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and
Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 13
3.2 Symptoms 15
4 Vaccination Recommendations
and Coverage Rates 17
4.1 US 17
4.1.1 Vaccination
Recommendations and Policies 17
4.1.2 Vaccination Coverage 17
4.1.3 Clinical Practice 19
5 Competitive Assessment 21
5.1 Overview 21
5.2 Strategic Competitor
Assessment 21
5.3 Product Profiles 23
5.3.1 Gardasil 23
5.3.2 Cervarix 29
6 Unmet Need and Opportunity 34
6.1 Overview 34
6.2 Protection against Multiple
HPV Types 35
6.2.1 Unmet Need 35
6.2.2 Gap Analysis 36
6.2.3 Opportunity 37
6.3 Vaccine Coverage Rates 37
6.3.1 Unmet Need 37
6.3.2 Gap Analysis 38
6.3.3 Opportunity 38
6.4 Perception of Vaccine
Safety 39
6.4.1 Unmet Need 39
6.4.2 Gap Analysis 40
6.4.3 Opportunity 40
6.5 Awareness of HPV
Vaccination 41
6.5.1 Unmet Need 41
6.5.2 Gap Analysis 41
6.5.3 Opportunity 42
6.6 Affordability of HPV
Vaccines 42
6.6.1 Unmet Need 42
6.6.2 Gap Analysis 43
6.6.3 Opportunity 43
6.7 Coverage of HPV Types
Prevalent in Certain Populations 44
6.7.1 Unmet Need 44
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment